Table 2.
Scheme Number |
Treatment 1 | Treatment 2 | Pathway | Investigation | Phase | Identifier | First Posted | Status |
---|---|---|---|---|---|---|---|---|
1 | Imatinib Nilotinib Dasatinib |
Asciminib | BCR-ABL1 allosteric inhibitor | Frontline combination in CP- CML | II | NCT03906292 | 2019 | Recruiting |
2 | none | Asciminib | BCR-ABL1 allosteric inhibitor | Efficacy of ABL001 versus Bosutinib in CP-CML patients previously treated with TKIs | III | NCT03106779 | 2017 | Recruiting |
3 | Dasatinib | Asciminib | BCR-ABL1 allosteric inhibitor | Combination in CML in lymphoid blast crisis | I | NCT03595917 | 2018 | Recruiting |
4 | Imatinib | Asciminib | BCR-ABL1 allosteric inhibitor | Efficacy and safety of combination in patients with CP-CML | II | NCT03578367 | 2018 | Recruiting |
5 | Imatinib Nilotinib Dasatinib |
Asciminib | BCR-ABL1 allosteric inhibitor | Oral ABL001 in CML Patients | I | NCT02081378 | 2014 | Recruiting |
6 | Imatinib | Cytarabine | DNA synthesis inhibitor | Combination in patients with CML | II | NCT00022490 | 2003 | Terminated |
7 | Imatinib | Cytarabine | DNA synthesis inhibitor | Combination in patients with CML | I/II | NCT00015834 | 2003 | Completed |
8 | Dasatinib | SAHA (Vorinostat) |
HDAC inhibitor | Combination in treating patients with accelerated phase or BP- CML | I | NCT00816283 | 2009 | Completed |
9 | Imatinib | Panobinostat (LBH589) |
HDAC inhibitor | Safety and tolerability of LBH589 combined with imatinib in CML patients in MCR | I | NCT00686218 | 2008 | Completed |
10 | Imatinib | Decitabine | DNA methyltransferase inhibitor | Combination in patients with CML | II | NCT00054431 | 2003 | Completed |
11 | Dasatinib | Venetoclax | BCL2 inhibitor | Combination in treating patients with BCR-ABL1 positive early chronic phase | II | NCT02689440 | 2016 | Recruiting |
12 | Ponatinib | Venetoclax Dexamethasone | BCL2 inhibitor Anti-inflammatory |
Triple combination in BCR-ABL positive relapsed CML | I/II | NCT03576547 | 2018 | Recruiting |
13 | Imatinib | Oblimersen | bcl-2 antisense oligodeoxynucleotide | Oblimersen and Imatinib in treating patients with CML | II | NCT00049192 | 2003 | Completed |
14 | Imatinib | Hydroxychloroquine | Autophagy inhibitor | Effectiveness of combination on BCR/ABL levels in CML patients in MCR | II | NCT01227135 | 2010 | Unknown |
15 | Imatinib | Everolimus (RAD001) | mTOR inhibitor | Combination in patients in CP-CML who are not in CCR after previous Imatinib | I/II | NCT00093639 | 2004 | Completed |
16 | Imatinib | Temsirolimus | mTOR inhibitor | Temsirolimus and Imatinib in treating patients with CML | I | NCT00101088 | 2005 | Terminated |
17 | Dasatinib | PF04449913 (Glasdegib) |
Smo antagonist HH inhibition |
Study of PF-04449913 in select hematologic malignancies | I | NCT00953758 | 2009 | Completed |
18 | Imatinib | Interferon-α | Immunomodulatory effect | INF-α and Imatinib in CML patients | II | NCT00045422 | 2003 | Completed |
19 | Imatinib | Pioglitazone | PPARγ agonist STAT5 inhibition |
Combination in patients with relapsed CML | II | NCT02767063 | 2016 | Terminated |
20 | Imatinib | Pioglitazone | PPARγ agonist STAT5 inhibition |
Efficiency of combination to treat CML | II | NCT02687425 | 2016 | Unknown |
21 | TKIs | Pioglitazone | PPARγ agonist STAT5 inhibition |
Pioglitazone and TKI in patients with relapsed CML | II | NCT02730195 | 2019 | Terminated |
22 | Dasatinib | Cyclosporine | IL-2 inhibitor | Combination in patients with CML refractory or intolerant to imatinib | I | NCT01426334 | 2011 | Terminated |
23 | Pioglitazone | Avelumab (Anti-PD-L1) | PPARγ agonist STAT5 inhibition PD-1/PD-L1 inhibition |
Therapies in combination or sequentially with TKIs in CP-CML patients in CCR (ACTIW) | I/II | NCT02767063 | 2016 | Recruiting |
24 | Imatinib Nilotinib Dasatinib |
Pembrolizumab (Anti-PD-1) | PD-1/PD-L1 inhibition | Pembrolizumab and TKIs in CML patients with persistently detectable MRD | II | NCT03516279 | 2018 | Recruiting |
25 | Dasatinib Nilotinib |
Ruxolitinib | JAK1/2 selective inhibitor | Ruxolitinib phosphate and Dasatinib or Nilotinib in treating CML patients | II | NCT03654768 | 2018 | Recruiting |
26 | Nilotinib | Ruxolitinib | JAK1/2 selective inhibitor | Ruxolitinib in treating participants with CML with MRD after TKIs | I/II | NCT01751425 | 2012 | Active, not recruiting |
27 | Nilotinib | Ruxolitinib | JAK1/2 selective inhibitor | Nilotinib/Ruxolitinb therapy for TKI resistant Ph-Leukemia | I//II | NCT01914484 | 2013 | Unknown |
28 | Nilotinib | Ruxolitinib | JAK1/2 selective inhibitor | Combination in CP-CML Patients | I | NCT01702064 | 2012 | Completed |
29 | Nilotinib | Peginterferon α2b | Immunomodulatory effect | Evaluation of TKI and INF-α | III | NCT01657604 | 2012 | Active, not recruiting |
30 | Imatinib Nilotinib |
Peginterferon α2b | Immunomodulatory effect | Imatinib or Nilotinib with Pegylated Interferon-α2b in CML | II | NCT00573378 | 2007 | Withdrawn |
31 | Dasatinib | Peginterferon α2b | Immunomodulatory effect | Safety and efficacy of combination in newly diagnosed CML (NordCML007) | II | NCT01725204 | 2012 | Completed |
32 | Bosutinib | Ropeginterferon | Immunomodulatory effect | Long-acting low dose Ropeginterferon for CML treated with Bosutinib from diagnosis | II | NCT03831776 | 2019 | Recruiting |
33 | Nilotinib | Sonidegib (LDE225) | Smo antagonist HH inhibition |
Combination in CML patients who developed resistance to prior therapy | I | NCT01456676 | 2011 | Completed |
34 | Dasatinib | BMS-833923 | Smo antagonist HH inhibition |
Combination therapy in CML | I/II | NCT01218477 | 2010 | Completed |
35 | Dasatinib | BMS833923 | Smo antagonist HH inhibition |
Dasatinib combo with Smo antagonist | II | NCT01357655 | 2011 | Terminated |
36 | Dasatinib | PF04449913 | Smo antagonist HH inhibition |
Study in select hematologic malignancies | I | NCT00953758 | 2009 | Completed |
37 | Imatinib | Zarnestra | Farnesyltransferase inhibitor | Zarnestra and Gleevec in CP- CML | I | NCT00040105 | 2002 | Completed |
38 | Imatinib | Lonafarnib | Farnesyltransferase inhibitor | Lonafarnib and Gleevec in CML | I | NCT00047502 | 2002 | Completed |
39 | none | Sorafenib (BAY43-9006) | Raf/VEGFR/PDGFR inhibitor | Raf kinase inhibitor BAY 43-9006 in CML patients resistant to Gleevec | II | NCT00661180 | 2008 | Completed |
40 | Imatinib | Vatalanib (PTK 787) | VEGFR inhibitor | Combination in patients with BP-CML | I/II | NCT00088231 | 2004 | Completed |
41 | Dasatinib | BP1001 | Grb2 inhibitor | Combination of liposomal Grb2 antisense oligonucleotide with Dasatinib in CML patients | I/II | NCT02923986 | 2016 | Recruiting |
42 | none | MK0457 | Aurora kinase inhibition | MK0457 in CML patients (0457-003) | I | NCT00111683 | 2005 | Completed |
43 | Dasatinib | MK0457 | Aurora kinase inhibition | Evaluation of efficacy and safety in patients with CML | I | NCT00500006 | 2007 | Terminated |